drugset / Trial / NCT01067989
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature. This study is meant to test the therapeutic potential of an anti-angiogenic treatment strategy by combining all these agents for metastatic breast cancer patients.
Timeline
- Start
- 2010-03
- Primary completion
- 2014-04
- Completion
- 2014-04
Outcome
Outcome not reported
Stopped: “No satisfactory acrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 500 mg | — |
| Subject | Celecoxib | Other / unclassified | 200 mg | — |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | — |
| Subject | Methotrexate | Small molecule | 2.5 mg | — |
| Subject | Pamidronate | Small molecule | 90 mg | Intravenous |
| Subject | Zoledronate | Other / unclassified | 4 mg | Intravenous |